VIVEbiotech S.L, has been the beneficiary of the Iniciativa Transmisiones 2023, funded by the CDTI with the collaboration of the Ministry of Science and Innovation of the Spanish Government. File number EXP 00162813 / MIG-20232031.
The SMART-VLPs project aims to revolutionize the design and production of virus-like particles (VLPs) for use in advanced therapies. Using artificial intelligence and DNA biotechnology, we seek to develop optimized lentiviral vectors to improve the efficiency and safety of gene editing and gene therapy-based treatments.
This effort is possible thanks to the collaboration of a first level consortium, composed of leading biotechnology and health entities:
- VIVEbiotech – Lentiviral vector development and production- project leader.
- OneChain Immunotherapeutics – Specialists in CAR-T therapies.
- Integra Therapeutics – Development of gene editing technologies.
- Universitat Pompeu Fabra (UPF) – Research in synthetic biology and gene editing.
- Instituto de Biología Molecular de Barcelona – CSIC – AI-based protein design.
- CIEMAT-CIBERER – Development of gene therapies for hematopoietic stem cells.
Through this project, we promote innovation in the field of advanced therapies, with the aim of improving the efficacy of treatments for genetic and oncological diseases, and contributing to the advancement of industrial biotechnology in Spain.